Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma: Cambridge, UK Monday, January 20, 2025, 09:00 Hrs [IS ...

Cambridge: AstraZeneca has announced that the Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) in ...

AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib), for first-line use in mantle cell ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

AstraZeneca's Calquence gains FDA approval for untreated mantle cell lymphoma, supported by data showing improved survival and reduced disease progression.

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

AstraZeneca's Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreate ...

The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...

On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...